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Abstract
Background:  Bone morphogenetic proteins (BMPs) regulate essential processes during
organogenesis, and a functional understanding of these secreted proteins depends on identification
of their target cells. In this study, we generate a transgenic reporter for organogenesis studies that
we use to define BMP pathway activation in the developing kidney.
Results: Mouse strains reporting on BMP pathway activation were generated by transgenically
expressing β-galactosidase under the control of BMP responsive elements from Id1. Reporter
expression corresponds well with immunoassays for pathway activation in all organs studied,
validating the model. Using these reporters we have generated a detailed map of cellular targets of
BMP signaling in the developing kidney. We find that SMAD dependent BMP signaling is active in
collecting duct trunks, but not tips. Furthermore, glomerular endothelial cells, and proximal
nephron tubules from the renal vesicle stage onward show pathway activation. Surprisingly, little
activation is detected in the nephrogenic zone of the kidney, and in organ culture BMP treatment
fails to activate SMAD dependent BMP signaling in nephron progenitor cells. In contrast, signaling
is efficiently induced in collecting duct tips.
Conclusion: Transgenic reporters driven by control elements from BMP responsive genes such
as Id1 offer significant advantages in sensitivity and consistency over immunostaining for studies of
BMP pathway activation. They also provide opportunities for analysis of BMP signaling in organ and
primary cell cultures subjected to experimental manipulation. Using such a reporter, we made the
surprising finding that SMAD dependent BMP signaling is inactive in nephron progenitors, and that
these cells are refractory to activation by applied growth factors. Furthermore, we find that the
BMP pathway is not normally active in collecting duct tips, but that it can be ectopically activated
by BMP treatment, offering a possible explanation for the inhibitory effects of BMP treatment on
collecting duct growth and branching.
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Background
Bone morphogenetic protein (BMP) signaling plays
diverse and essential roles during development of numer-
ous organ systems such as the heart [1-3], lung [4,5] and
kidney [6-8]. Signaling is initiated when ligands bind cell
surface serine threonine kinase receptors that in their turn
phosphorylate the receptor associated transcription fac-
tors SMAD 1, 5 and 8 (R-SMADs) [9]. Phosphorylated R-
SMADs associate with the common SMAD, SMAD4 and
are translocated into the nucleus where they bind DNA in
association with other factors. Transcriptional outcomes
are determined by association with general transcriptional
activators such as p300 and CBP [10], or by association
with repressors such as Suv39h [11] or CtBP [12]. The
SMAD Binding Element (SBE), GTCT and the GC-rich
consensus motif GNCGCC [13-15], confer relatively low
affinity and specificity to the SMAD:DNA interaction,
necessitating association with other transcription factors
such as ZFP423 (OAZ) [16] for efficient DNA binding.
Interestingly, this combinatorial requirement for binding
can be bypassed by concatamerizing the basic SMAD
binding motifs. This approach has been successful in gen-
erating synthetic genes for use as signaling reporters in
vitro [16,17]. The immediate early BMP response gene Id1
has been of particular interest as its promoter region con-
tains a natural concatamer of SMAD binding motifs [15],
potentially enabling its activation through SMAD binding
alone. This natural concatamer, known as the BMP
Responsive Element (BRE) has been used to generate both
an in vitro BMP reporter [15] and in vivo reporters
[18,19].
Although cellular targets for BMP signaling have been
defined in some developing tissues by conditional inacti-
vation of BMP receptors [20-25] and Smad transcription
factors [26], the full complement of cellular targets of
BMP signaling in many organ systems is not known. To
further clarify which cells respond transcriptionally to
SMAD mediated BMP signals during mouse organogene-
sis, we have generated a novel in vivo reporter by cloning
a concatamer of the Id1 BRE upstream of the heat shock
protein 1A (Hspa1a or Hsp68) promoter fused to β-galac-
tosidase cDNA [27]. We find that β-galactosidase expres-
sion is regulated by BMPs in vitro, and can show by
comparison with staining for nuclear phosphorylated
SMAD 1, 5 and 8 that domains of BMP pathway activation
can be recapitulated in all organs studied. In the kidney,
we find that the BMP signaling pathway is highly activated
in collecting ducts, developing nephron tubules and
glomeruli, but surprisingly it is inactive in the nephron
progenitor cell population, which is thought to respond
to BMP signaling. Reporter gene activation is faithfully
maintained in organ culture, confirming the versatility of
this mouse strain for studies of organogenesis. Taken
together, our study augments the current understanding
of SMAD dependent BMP signaling during kidney devel-
opment by identifying cellular targets.
Results and discussion
The BRE-Hspa1a-lacZ (BRE-lacZ) transgenic reporter 
strain
To generate a mouse in which cells responding to BMP
signaling are labeled by β-galactosidase expression, we
derived a transgenic strain using a construct containing a
concatamerized SMAD1/5/8 binding site from the mouse
Id1 gene [15], upstream of the Hspa1a promoter (-873 to
+5 relative to the translational start) fused to the β-galac-
tosidase cDNA followed by an SV40 polyadenylation sig-
nal [27,28] (Fig. 1A). The BMP responsive cis-regulatory
element has previously been successfully used to generate
an in vitro BMP transcriptional reporter for use in cell cul-
ture [15], and an in vivo BMP reporter for early mouse
development [18]. Both of these reporters employ the
adenovirus major late promoter. For organogenesis stud-
ies, we chose the Hspa1a promoter as its high fidelity dur-
ing development of diverse organ systems is well
documented [29,30]. Furthermore, the Hspa1a-lacZ
fusion construct has previously been successfully used to
generate an in vivo reporter for retinoic acid signaling
[31]. The Hspa1a promoter alone does not drive tissue
specific expression, but does contain a heat shock ele-
ment, causing ubiquitous activation of the reporter at
42°C [27]. Uniquely, therefore, the transgene can be heat
induced in cells in which β-galactosidase is not expressed,
to control for transcriptional silencing of the transgene.
To allow screening for transgenic reporters with high sig-
nal strength, we chose to derive transgenic mice from
embryonic stem cells (ESCs) rather than using pronuclear
injection. To evaluate the frequency in our experimental
system of β-galactosidase activation caused by positional
activation of the reporter gene, we performed a parallel
control experiment in which Hspa1a-lacZ was electropo-
rated into ES cells with the pgk-neor cassette, and drug
resistant clones were assayed for reporter gene expression
following BMP4 treatment. Of 96 drug resistant colonies
screened, one was found to express β-galactosidase, indi-
cating that the frequency of confounding constitutively β-
galactosidase expressing clones was less than 2%. After
selecting drug resistant ESCs coelectroporated with linear-
ized BRE-Hspa1a-lacZ and selection cassette, individual
colonies were screened for β-galactosidase expression in
response to BMP4 treatment by X-gal staining (Fig. 1B).
Approximately 13% (24/192) of drug resistant colonies
expressed the reporter gene. As extensive BMP pathway
activation is required for maintenance of undifferentiated
ESCs [32], basal BMP reporter activation could not be
entirely overcome. Therefore, it should be noted that col-
onies were selected on the basis of increase in X-gal stain-
ing relative to the unstimulated state. Three colonies withBMC Developmental Biology 2008, 8:86 http://www.biomedcentral.com/1471-213X/8/86
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Figure 1 (see legend on next page)
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induced responses to ligand were selected for blastocyst
injection, resulting in establishment of 2 lines derived
from separate transgene integration events: 1C10 and 2F3.
Sagittal sectioning with subsequent X-gal staining of
E10.5 and E17.5 embryos revealed a highly similar β-
galactosidase expression pattern in these two strains (See
additional file 1: straincomparison.pdf). As the 1C10
strain displayed more intense staining, it was used for sub-
sequent experiments, and is hereafter designated BRE-
lacZ.
BMP inducibility of β-galactosidase expression in BRE-
lacZ mice was verified by stimulation of murine embry-
onic fibroblasts (MEFs) with recombinant BMP4 and
BMP7 (Fig. 1C, D). After stimulation with either of these
ligands, β-galactosidase accumulates intracellularly in a
dose-dependent manner. This can both be visualized by
X-gal staining (Fig. 1C), and quantified by colorimetric
assay using the ONPG substrate (Fig. 1D), demonstrating
that the reporter is significantly activated by BMP4. As
with ESCs, the basal level of reporter gene activation in
MEFs is relatively high. This can be overcome to some
degree by culture in serum free medium for 24 to 48 hours
or addition of the BMP antagonist noggin to cell culture
medium, but cannot be entirely quenched. A possible
explanation for this residual basal pathway activation is
that BMPs are actively produced in embryonic fibroblasts
[33], and the extracellular antagonist noggin may be inca-
pable of quenching signaling initiated intracellularly by
BMP ligands. To explore this possibility, we compared
lacZ production with the abundance of phosphorylated
SMAD 1, 5 and 8 transcription factors (pSMAD1/5/8) in
untreated and noggin treated BRE-lacZ fibroblasts (Fig.
1E). Although culture with noggin results in a significant
reduction of both lacZ production and pSMAD1/5/8,
basal activation does remain, demonstrating that extracel-
lular BMP antagonism does not quench endogenous BMP
signaling in fibroblasts. Previous experiments employing
MEFs in which Smad4 had been conditionally inactivated
demonstrated that TGFβ superfamily pathway activation
is required for growth of these cells (data not shown and
[34]), and thus basal pathway activation is anticipated in
these actively growing cells.
From these experiments, we propose that domains of β-
galactosidase expression correlate with BMP pathway acti-
vation in vivo rather than transgene activation due to
positional integration effects as we find that transgenic
animals generated from 2 separate ES cell clones display
highly similar expression patterns. Furthermore, based on
in vitro ligand stimulation assays we conclude that the
BRE-lacZ transgenic strain expresses β-galactosidase in
response to BMP.
BRE-lacZ reporter activation correlates with nuclear 
accumulation of phosphorylated SMAD 1, 5 and 8
To definitively assay the degree to which in vivo reporter
gene activation corresponds with pathway activation, we
compared sections immunohistochemically stained for
pSMAD1/5/8 with X-gal stained sections of BRE-lacZ
embryos (Fig. 2). Nuclear pSMAD1/5/8 staining is a
widely used marker of BMP pathway activation in diverse
organ systems and species [35-37], reporting on activation
of BMP-induced R-SMADs upon ligand stimulation.
E12.5 was chosen as the most informative time point for
these studies for two reasons. First, organogenesis is well
underway, enabling comparison between nuclear
pSMAD1/5/8 accumulation and reporter gene activation
in most systems. Second, the paraformaldehyde fixed
E12.5 embryo is readily sectioned, without tearing due to
uneven fixation. Serial sagittal sections through 3 entire
E12.5 wild type embryos were immunohistochemically
stained with a polyclonal pSMAD1/5/8 antiserum (Cell
Signaling Technology), and representative sections are
shown (Fig. 2). Negative controls consisting of E12.5 wild
type embryos stained either with secondary antibody
alone, or with X-gal showed negligible background signal
(See additional file 2: staining controls.pdf). Low power
micrographs of medial E12.5 sections from wild type mice
immunostained for pSMAD1/5/8 and X-gal stained BRE-
lacZ reporters show extensive overlap in specificity of
staining (Fig. 2A, B). Furthermore, the agreement in areas
Strategy for generating the BRE-lacZ reporter strain Figure 1 (see previous page)
Strategy for generating the BRE-lacZ reporter strain. A. The BRE-lacZ transgene consists of a duplex of the CAGC1/2 
sequence, and a duplex of SMAD binding elements 2 and 3 derived from the mouse Id1 gene [15] upstream of the Hspa1a pro-
moter fused to β-galactosidase and the SV40 polyadenylation signal [27,28]. B. ES cell transgenesis was used to facilitate screen-
ing for signal strength of the reporter: ES cells were co-electroporated with BRE-Hspa1a-lacZ and a pgk-neo drug selection 
cassette, drug resistant colonies were isolated and screened for strong β-galactosidase expression in response to treatment 
with 25 ng/ml BMP4. Three clones were selected for blastocyst injection. C. Responsiveness of murine embryonic fibroblasts 
(MEFs) derived from BRE-lacZ positive E12.5 embryos was assessed by X-gal staining of cells. D. Responsiveness of MEFs to 
BMP treatment was verified by quantitative assay of β-galactosidase activity using the ONPG substrate. E. BRE-lacZ MEFs cul-
tured in serum free medium for 48 hours with and without the addition of noggin were assayed for β-galactosidase activity 
using the ONPG substrate. For comparison of BMP pathway activation, cell extracts were immunoblotted for pSMAD1/5/8. 
Comparable loading of protein on the membrane was verified by immunoblot with β-tubulin.BMC Developmental Biology 2008, 8:86 http://www.biomedcentral.com/1471-213X/8/86
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Figure 2 (see legend on next page)
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devoid of staining for both pSMAD1/5/8 and X-gal is
notable in this overview, indicating that the reporter is
sensitively and specifically reporting on BMP pathway
activation, without spurious ectopic activation. Domains
of reporter gene activation can also be seen at earlier
developmental time points (Fig. 2C, additional file 1:
straincomparison.pdf). Specifically, at E12.5 pathway
activation with concomitant reporter gene activation is
seen in the trigeminal ganglion (Fig. 2D, E), snout (Fig.
2D, F), forebrain (Fig. 2A, G), eye (Fig. 2H, I), dorsal root
ganglia (Fig. 2J, K) and neural tube (Fig. 2L, M). One
exception to the strong correlation between nuclear
pSMAD1/5/8 staining and reporter gene activation is the
embryonic heart, which does not show noticeable
pSMAD1/5/8 staining in this assay. However, immuno-
histochemistry reveals relatively weak localized nuclear
staining in this organ when fixed in isolation from the
embryo (Fig. 3O). Furthermore, a previous study has
reported nuclear pSMAD1/5/8 staining in cardiomyocytes
of midgestation embryos [38], and we therefore conclude
that the pathway indeed is activated in the heart, but that
our immunoassay is not sufficiently sensitive for its detec-
tion.
Based on the comparison with nuclear accumulation of
pSMAD1/5/8, we are confident that the BRE-lacZ faith-
fully reports on domains of BMP signaling in vivo.
BRE-lacZ reporter gene activation in developing organ 
systems
To validate the reporter for organogenesis studies, we per-
formed analyses on a variety of tissues at 3 distinct time
points during development: E10.5, E12.5, and E17.5.
Additionally, immunostaining for pSMAD1/5/8 was per-
formed to allow correlation of pathway activation with
reporter gene expression.
Gut (Fig. 3A–D)
At both E12.5 and E17.5, the reporter is active in the epi-
thelium of the developing gut. In the mesenchyme, com-
paratively less staining is apparent, and at E17.5 few
stained mesenchymal cells can be seen (Fig. 3C). Nuclear
pSMAD1/5/8 is seen in a subset of epithelial cells at E12.5
(Fig. 3B), but in all epithelial cells at E17.5 (Fig. 3D). This
staining pattern correlates well with previous reports,
which have shown extensive nuclear accumulation of
pSMAD1/5/8 in epithelial cells of the villus with absence
of signaling in most of the villus mesenchyme [39,40].
Liver (Fig. 3E–H)
Two distinct populations of β-galactosidase positive cells
can be seen from E10.5 through to E17.5: endothelial cells
lining vessels, and single cells throughout the liver paren-
chyme. Nuclear accumulation of pSMAD1/5/8 is seen in a
similar distribution (Fig. 3G).
Lung (Fig. 3I–L)
The reporter is active in epithelium and mesenchyme
from E10.5 through E17.5. In bronchiolar epithelia, path-
way activation is not uniform, with signaling and non-sig-
naling cells interspersed (Fig. 3J, 3L). This pattern is
reflected in our pSMAD1/5/8 staining (Fig. 3K), and in
pSMAD1/5/8 staining previously reported [4]. In agree-
ment with this, reporter gene activation strongly resem-
bles the expression pattern of Follistatin like 1 (Fstl1,
TGFβ stimulated clone 36), a BMP response gene [41].
Reporter gene activation in lung mesenchyme is not
apparent at E10.5, but widespread at E12.5 and E17.5. Lit-
tle reporter activity is seen in alveolar epithelia, whereas
strong staining can be seen in the vessel rich mesenchyme
between alveoli. Again, this pattern corresponds closely to
previously reported pSMAD1/5/8 staining, and the
expression pattern of Fstl1, which is localized mainly to
endothelial cells and smooth muscle in the mesenchyme
[41].
Comparison of BRE-lacZ with nuclear accumulation of phosphorylated SMAD 1, 5 and 8 Figure 2 (see previous page)
Comparison of BRE-lacZ with nuclear accumulation of phosphorylated SMAD 1, 5 and 8. A. In general, immunos-
taining for nuclear accumulation of phosphorylated forms of SMADS 1, 5 and 8 (pSMAD1/5/8) is weak, but strongest signals are 
seen in forebrain, snout, dorsal root ganglia, neural tube and kidney. B. At E12.5, intense reporter gene activation can be seen 
in areas overlapping with nuclear pSMAD1/5/8 staining: forebrain, snout, dorsal root ganglia, ventral neural tube, kidney and 
heart. C. At E10.5, reporter gene activation is intense in heart, forebrain, snout, neural tube, dorsal root ganglia and dorsal 
aorta as well as blood vessels of the head. D. Vibratome section of BRE-lacZ head showing strong signal in trigeminal ganglion 
(TrG) and snout (Sn). E. Abundant nuclear pSMAD1/5/8 is seen in the trigeminal ganglion. F. Nuclear pSMAD1/5/8 colocalizes 
with BRE-lacZ expression in the snout. G. Nuclear pSMAD1/5/8 in forebrain. H, I. Comparison between BRE-lacZ and 
pSMAD1/5/8 in the eye shows significant overlap in the corneal epithelial layer and lens (insets). J, K. β-galactosidase and 
nuclear pSMAD1/5/8 overlap in cells of the dorsal root ganglion. L, M. BMP signaling can be detected by both BRE-lacZ and 
pSMAD1/5/8 in the ventral and dorsal neural tube (square brackets, insets), but not in the intermediate region. Abbreviations: 
DA: dorsal aorta, CP: choroid plexus, DRG: dorsal root ganglion, Fb: forebrain, Ht: heart, Ki: kidney, Li: liver, Lu: lung, NT: 
neural tube, Sn: snout, TrG: trigeminal ganglion.BMC Developmental Biology 2008, 8:86 http://www.biomedcentral.com/1471-213X/8/86
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Figure 3 (see legend on next page)
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Heart (Fig. 3M–P')
A consistent pattern is seen from E10.5 (Fig. 3M) to E17.5
(Fig. 3N) (E12.5 not shown) with reporter activation in
myocardium and endothelium, but with little or no acti-
vation in endocardial cushions and valves (Fig. 3P). E17.5
myocardium displays nuclear pSMAD1/5/8 staining (Fig.
3O), and a similar pattern has previously been reported in
cardiomyocytes of the E11.5 heart [38]. Nuclear
pSMAD1/5/8 accumulation in cardiomyocytes is not uni-
form in either of these studies, yet reporter gene activation
does appear to be. Likely explanations for this discrepancy
could be either that: i) The BMP pathway is indeed active
in all cardiomyocytes, but our immunoassay is only sensi-
tive enough to detect a subset of these, or ii) BMP signal-
ing is cyclical in these cells, causing β-galactosidase to
accumulate in the cell during a period of activation of the
pathway, leading to staining in cells in which the pathway
is inactive. Regardless of the explanation for this discrep-
ancy, our data suggests that cardiomyocytes actively
respond to BMP signaling on a population basis. BMP sig-
naling is highly regulated in the endocardial cushions and
valves of the developing heart, with few stained cells in
the mesenchyme of either cushions (Fig. 3M) or semilu-
nar valves (Fig. 3P). Reporter gene activation can however
be seen in overlying endothelial cells (Fig. 3P'), which is
consistent with the pattern of nuclear accumulation of
pSMAD1/5/8. Consistent with our finding of strong BMP
pathway activation in myocardium and weak or absent
activation in endocardial cushions and developing valves,
Bmp2, 4, 5, 7, and 10 are all expressed in a semi-overlap-
ping pattern in myocardium [42-44], whereas the BMP
signaling inhibitors Smad6  and  Smad7  are vigorously
expressed in endocardial cushions [20,45].
Vasculature (Fig. 3Q, R)
Reporter gene activation and nuclear accumulation of
pSMAD1/5/8 are both primarily localized to endothelial
cells, although there is some staining in vessel walls.
Recent studies have shown that SMAD-dependent signal-
ing in endothelial cells is stimulated by BMP9 and BMP10
ligands activating the orphan ALK1 receptor [46,47]. Fur-
thermore, biologically active BMP9 is a circulating plasma
component in the human [48], consistent with the lumi-
nal activation of BMP signaling seen in the reporter mouse
strain.
Skin (Fig. 3S, T)
The reporter is differentially regulated in skin isolated
from the lumbar region of the embryo: In the basal layer,
little or no activation can be seen, whereas strong activa-
tion is seen in the suprabasal layer, and weak activation in
the subbasal layer. Furthermore, individual cells within
dermal papillae display activation. This data correlates
well with a recent report, which suggested that BMP sign-
Reporter gene activity in developing organs Figure 3 (see previous page)
Reporter gene activity in developing organs. A – D. In the developing gut, reporter gene activity is seen throughout the 
gut epithelium at both E12.5 (A) and E17.5 (C). Nuclear pSMAD1/5/8 staining is seen in a subset of epithelial cells at E12.5 (B, 
arrows), and all epithelial cells at E17.5 (D). Scattered cells in the mesenchyme show reporter gene activation (A, open arrow-
heads), similar to the pattern of nuclear pSMAD1/5/8 staining (B, arrows). In the villus of the small intestine, the majority of 
mesenchyme cells show neither reporter gene activation (C) nor nuclear pSMAD1/5/8 (D, inset). Likewise, the gut wall is 
largely devoid of reporter gene activation and nuclear pSMAD1/5/8 (C, D, inset) with the exception of some blood vessels. E – 
H. In the developing liver, reporter activation is seen in endothelial cells of vessels (asterisk), and in individual cells distributed 
through the liver parenchyme (open arrowheads). G. A similar distribution of nuclear pSMAD1/5/8 staining is seen (arrows, 
inset). H. Expression is maintained in the liver through development to E17.5. I – L. In the lung, the reporter is active in large 
airway epithelium from E10.5 (I) to E17.5 (L). A mixture of activated and non-activated cells can be seen in bronchiolar epithe-
lium (J, L), similar to the pattern of nuclear pSMAD1/5/8 staining (K, arrows, inset). In the E12.5 mesenchyme, sporadic 
reporter gene activation and nuclear pSMAD1/5/8 can be seen (J, K, arrows). In the E17.5 lung, no reporter gene activation is 
seen in alveolar epithelium, whereas widespread activation can be seen in the mesenchyme between alveoli (L, inset). M – P. In 
the heart, the reporter is active in myocardium from E10.5 (M) to E17.5 (N), overlapping with widespread nuclear pSMAD1/5/
8 (O, arrows). In endocardial cushions (M) and developing semilunar valves (N), reporter activation is limited to endocardial 
cells (P, open arrowheads), overlapping with nuclear pSMAD1/5/8 (P', arrows). Q – R. In blood vessels, overlapping reporter 
activation and nuclear pSMAD1/5/8 are seen in endothelial cells (Q, arrowheads, R, arrows). S – T. In skin, the basal layer is 
devoid of both reporter gene activation and nuclear pSMAD1/5/8, whereas the suprabasal layer stains strongly for both (T, 
inset). The reporter is weakly active in the subbasal layer. Single cells within the base of each dermal papilla display both 
reporter activation and nuclear pSMAD1/5/8 (S, T, insets). U – X. In the developing forelimb, reporter activation is seen in the 
interdigital region of the E12.5 limb (U). Reporter activation and nuclear pSMAD1/5/8 overlap in cartilage of the developing 
humerus (V, W). In cultures of E17.5 metatarsals, reporter activation is seen in cartilage, but is excluded from the calcified 
center, despite treatment with 50 ng/ml BMP4 (X). X'. An X-gal stained wild type metatarsal demonstrates absence of back-
ground staining. Abbreviations: Al: alveolus, Br: bronchiole, BL: basal layer, Ca: cartilage, CC: calcified center, Cush: endocar-
dial cushion, DP: dermal papilla, E: epithelium, IR: interdigital region, M: mesenchyme, Myo: myocardium, Sub: subbasal layer, 
Supra: suprabasal layer, Va: valve.BMC Developmental Biology 2008, 8:86 http://www.biomedcentral.com/1471-213X/8/86
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aling is required in dermal papilla cells for their hair
inductive properties [49]. Reporter activation is consistent
with nuclear pSMAD1/5/8 accumulation, with the excep-
tion of the subbasal layer. As noted for other organs, the
reporter is significantly more sensitive than the pSMAD1/
5/8 immunoassay, and the lack of staining in the subbasal
layer may be due either to weak SMAD expression, or to
limited SMAD phosphorylation.
Limb (Fig. 3U–X)
The reporter is activated in the interdigital region of the
E12.5 forelimb (Fig. 3U). Previous studies have identified
a role for BMP signaling in apoptosis of the interdigital
region [50], and this pattern of reporter gene activation is
consistent with pSMAD1/5/8 nuclear accumulation in the
developing autopod [51]. In the presumptive humerus at
E12.5, strong reporter activation is seen in proximal and
distal bone that contains resting and proliferative
chondrocytes, while little or no activation is seen in the
overlying perichondrium (Fig. 3V). Reporter gene activa-
tion correlates strongly with nuclear pSMAD1/5/8 in
chondrocytes, and little or no staining in the perichon-
drium of the developing humerus (Fig. 3W). Strong
nuclear accumulation of pSMAD1/5/8 has previously
been observed in chondrocytes, and conditional inactiva-
tion of BMP type I receptors demonstrates that BMP sign-
aling is required for cartilage condensation and
skeletogenesis of endochondral bone [52]. Furthermore,
compound inactivation of BMP2 and BMP4 indicate that
these may be the cognate ligands required for BMP-medi-
ated skeletogenesis [53]. To ascertain the degree of
reporter activation in mineralized tissue, we cultured met-
atarsal rudiments from E17.5 BRE-lacZ embryos with or
without 50 ng/ml BMP4 for 24 hours (Fig. 3X). The stain-
ing pattern is similar in both treated and untreated groups
(data not shown), with strong signal in condensing or
proliferative chondrocytes and a graded weaker signal
toward the presumptive ossification center (Fig. 3X, X').
In this analysis of organogenesis of liver, gut, lung, heart,
vasculature, skin, and bone, we find that there is a remark-
able consensus between reporter gene activation and
nuclear accumulation of pSMAD1/5/8. Furthermore, pat-
terns of BMP reporter expression largely coincide with
previous studies using the pSMAD1/5/8 antiserum. From
this survey, we conclude that the BRE-lacZ strain is an
appropriate tool for further detailed studies of organogen-
esis.
Identification of BMP responding cells in the developing 
kidney
Numerous studies have defined roles for BMP ligands in
development of the kidney. Bmp7  [7,8], Bmp4  [6] and
Bmp5 [54] are all required for appropriate nephrogenesis.
Interestingly, the molecular function of these ligands
appears to be interchangeable [55], indicating that unique
patterns of expression of these genes are decisive for devel-
opment of the kidney rather than their individual proper-
ties [29,43]. Although detailed expression data is available
for Bmp genes in the developing kidney [43,44,56], stud-
ies to define cellular targets of their gene products have
generated ambiguous results, complicating the interpreta-
tion of loss of function phenotypes. This is presumably
due to variability of reagents and protocols for detection
[57-62]. Using the BRE-lacZ mouse, we are able to estab-
lish an unambiguous map of SMAD dependent BMP
responses in the developing kidney, facilitating interpreta-
tion of loss of function mutants in the BMP pathway.
Mesonephros
In the E10.5 embryo, BMP signaling is activated in the
proximal pole of the mesonephric tubule, and little or no
activation can be detected in the distal pole, which con-
nects to the mesonephric duct (Fig. 4A). This pattern of
pathway activation corresponds closely with Bmp7 expres-
sion in these nephrons [56]. Uniform low level signaling
is seen in the mesonephric duct (Fig. 4B). Little is known
about the role of BMP signaling in development of the
primitive kidney in the mouse. However, loss of function
studies in the amphibian reveal a requirement for BMP
signaling both for formation of the pronephric duct and
tubule [63], indicating that activation of this signaling sys-
tem may also be a requirement for pro- and mesonephros
formation in the mammal.
Metanephros
Two developmental time points were chosen for studies
of metanephros development: E12.5 and E17.5. At E12.5,
the ureteric bud derived collecting duct migrates into the
metanephric blastema and induces the nephron progeni-
tor population, or nephrogenic mesenchyme. At this time
signaling is most prominent in the trunk of the collecting
duct, but not the tips or leading edges of these structures
and little pathway activation can be seen in the nephro-
genic mesenchyme (Fig. 4C, D). Within the blastema,
islands of BMP-signaling vasculature can be seen. This
pattern of signaling is corroborated by nuclear pSMAD1/
5/8 accumulation (Fig. 4E, F, G, H) and previously pub-
lished pSMAD1/5/8 immunostaining [61,62], showing
pathway activation specifically in trunks but not tips of
collecting ducts. In the E17.5 kidney, widespread activa-
tion of the pathway reporter is seen, with the exception of
the nephrogenic zone (Fig. 4I, J). Tubular structures at
numerous stages of differentiation and glomeruli display
reporter activation. This pattern largely corresponds to
nuclear accumulation of pSMAD1/5/8 (Fig. 4K, L),
although pSMAD1/5/8 staining is weak in nephron
tubules and in the glomerulus (Fig. 4L). To discern precise
locations of pathway activation, we generated a series of
high power micrographs, and performed molecularBMC Developmental Biology 2008, 8:86 http://www.biomedcentral.com/1471-213X/8/86
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Figure 4 (see legend on next page)
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marker analysis for structures lacking distinct morphol-
ogy.
Collecting ducts
To confirm that differential pathway activation in collect-
ing ducts is maintained from E12.5 to E17.5, we counter-
stained X-gal stained kidney tissue from E17.5 BRE-lacZ
embryos with the dolichos bifloris lectin, an established
marker for collecting ducts. Signaling is maintained in col-
lecting duct trunks from E12.5 to E17.5 (Fig. 4M, N), but
collecting duct tips are devoid of signal at both of these
time points. Interestingly, a requirement for BMP signal-
ing for collecting duct morphogenesis has recently been
revealed by tissue specific inactivation of the Alk3 BMP
receptor gene with the collecting duct specific Hoxb7cre
driver [25]. This contrasts with previous work in which it
was shown that inactivation of the Smad4 signal transduc-
tion mediator with the same cre driver has little or no
effect on kidney development [61]. This suggests that the
BMP receptor may mediate collecting duct morphogene-
sis through SMAD independent signaling in collecting
duct tips, possibly through activating the p38MAPK path-
way. Signaling by BMP7 through this pathway has previ-
ously been demonstrated in cultured collecting duct cells.
Interestingly, low doses of BMP7 stimulate morphogene-
sis of cultured collecting duct cells through the p38MAPK
pathway, whereas high doses of BMP7 negatively regulate
p38MAPK pathway activation in a SMAD dependent fash-
ion [64]. The complex regulation of collecting duct mor-
phogenesis by BMP signaling is underscored by the
outcome of inactivation of Alk3 in this cell population:
Compared to wild type mice, Hoxb7cre; Alk3ca mice dis-
play an early increase in collecting duct branching fol-
lowed by a reduction in growth and branching later in
development [25].
Nephrogenic zone
The nephrogenic zone of the developing kidney is the
region of de novo nephron formation, and is composed of
peripheral stromal cells, nephrogenic mesenchyme
(nephron progenitor cells), collecting duct tips and pretu-
bular aggregates, the nascent epithelial aggregates that will
give rise to nephrons (Fig. 4O). With the exception of a
very small number of single cells in the vicinity of the
nephrogenic mesenchyme, there is no pathway activation
in this zone of the kidney (Fig. 4O). This is remarkable,
considering that BMP signaling is required for survival of
nephrogenic mesenchyme cells, and that Bmp7 null kid-
neys are prematurely depleted of nephron progenitors
[8,55,65]. Furthermore, the Bmp7 loss of function pheno-
type has been correlated with the non-redundant expres-
sion of Bmp7 in the nephron progenitor population [43],
indicating that active BMP signaling does indeed occur in
the nephrogenic zone. Several alternative explanations to
BMP pathway activation in the developing kidney Figure 4 (see previous page)
BMP pathway activation in the developing kidney. A. At E10.5, strong reporter activation is seen in mesonephric 
tubules within the intermediate mesoderm. B. Weak reporter activation is seen in the Wolffian duct at E10.5. C. At E12.5, the 
reporter is active in the trunk of the collecting duct, and islands of vascular activation can be seen throughout the mesenchyme. 
D. Collecting duct tips show no reporter activation. Likewise, nephrogenic mesenchyme shows little or no reporter activation. 
E. Nuclear pSMAD1/5/8 staining is seen in the center of the E12.5 kidney, with renal vesicles and collecting duct trunks showing 
the most intense staining. F. Very few cells interspersed within the nephrogenic mesenchyme display nuclear pSMAD1/5/8 
staining. Cells of the renal vesicle, however display extensive nuclear pSMAD1/5/8 accumulation. G. Numerous cells within the 
collecting duct trunk display nuclear pSMAD1/5/8 staining (arrows). H. Little pSMAD1/5/8 staining is seen in collecting duct 
tips. I. Reporter activation is seen in tubules and glomeruli throughout the E17.5 kidney from the subcortical layer to the nas-
cent papilla. J. Enlargement of the boxed region in panel D. Reporter activation is seen in tubules and glomeruli, but is largely 
absent from the nephrogenic zone. K. Nuclear pSMAD1/5/8 staining is seen in cells of the glomerulus, tubules and nascent 
nephrons. Nuclear pSmad1/5/8 staining is sparse in the nephrogenic zone. L. Enlargements of pSmad1/5/8 stained nephrogenic 
zone, collecting ducts trunks, nephron tubules, and glomerulus showing localization of nuclear pSmad1/5/8 accumulation 
(arrows). M. Costaining with DBA lectin shows reporter activation in collecting duct trunks. N. No activation can be seen in 
DBA staining collecting duct tips. O. In the nephrogenic zone, activation can be seen only in nascent nephron structures, and 
individual cells adjacent to the nephrogenic mesenchyme (arrowheads). P. Reporter activation can be seen throughout the 
early comma shaped body with the exception of the proximal podocytes. Q. At later stages in the comma shaped body, signal-
ing is concentrated to the presumptive proximal tubule and Bowman's capsule. R. In the s shaped body, pathway activation is 
seen in the proximal tubule and Bowman's capsule. S. Costaining with lotus lectin shows that the pathway remains active in 
more mature convoluted proximal tubules of the medulla. T. Distal tubules characteristically located at the vascular pole of the 
glomerulus display little pathway activation. Cells of Bowman's display pathway activation, but podocytes do not. U, V. Adjacent 
sections from E17.5 BRE-lacZ embryos stained for reporter activation (U) and the endothelial marker CD31 (V) show pathway 
activation in the glomerular capillary. Mesangial cells display little activation. Abbreviations: BC: Bowman's capsule, Caps: Cap-
sule, CD tip: Collecting duct tip, CD trunk: collecting duct trunk, DT: distal tubule, G: glomerulus, GC: glomerular capillary, 
MD: mesonephric (Wolffian) duct, M: medulla, Ma: mesangium, MT: mesonephric tubule, NM: nephrogenic mesenchyme, NZ: 
nephrogenic zone, P: podocyte, PT: proximal tubule, RV: renal vesicle, T: tubules, US: urinary space, V: vasculature.BMC Developmental Biology 2008, 8:86 http://www.biomedcentral.com/1471-213X/8/86
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this apparent contradiction can be formulated. First, the
Id1 reporter might be inactive specifically in the nephro-
genic zone of the kidney, whereas other BMP responsive
genes are not. To address this, we compared in situ hybrid-
ization assays for the known BMP responsive genes Id1,
Id3 and Bambi in the Genepaint database (Genepaint.org,
see additional file 3: ISH.doc). We find that none of these
genes are expressed in the nephrogenic zone, whereas they
are expressed in a pattern that appears to overlap with
BRE-lacZ reporter activation in the medulla of the kidney.
This strongly supports the contention that BMP signaling,
rather than just Id1 expression is inactive in the nephro-
genic zone. Second, BMP signaling may be mediated
through SMAD independent rather than SMAD depend-
ent signaling pathways, for example the p38MAPK path-
way [64]. Third, BMP signals to the very small population
of BMP responding cells adjacent to the nephrogenic mes-
enchyme may be required for maintenance of the nephro-
genic mesenchyme. Fourth, BMP signals emanating from
the nephrogenic mesenchyme may be required by a
responding cell population outside the nephrogenic zone,
such as developing nephrons, to maintain the nephro-
genic mesenchyme. Fifth, BMP signaling may be required
at a time point before establishment of the nephrogenic
zone for survival of the nephrogenic mesenchyme popu-
lation.
Developing nephrons
In the nascent renal vesicle, little pathway activation can
be seen (Fig. 4O). Signaling becomes active throughout
the early comma shaped body with the exception of the
nascent podocytes (Fig. 4P), and this domain of pathway
activation resolves to the presumptive proximal tubule
section as the structure matures, with little signaling seen
in the presumptive distal tubule. In the presumptive
glomerulus of the late stage comma shaped body, signal-
ing is seen in Bowman's capsule, but the podocytes
remain devoid of activation (Fig. 4Q). This pattern of
pathway activation is maintained in the s shaped body,
where signaling can be seen in the proximal tubule, Bow-
man's capsule, and capillaries forming within the vascular
cleft. The distal tubule and podocytes remain free from
signaling (Fig. 4R). Costaining with lotus lectin demon-
strates that BMP signaling is maintained in the proximal
tubule as it matures (Fig. 4S). Little pathway activation
can be seen in mature distal tubules (Fig. 4T).
Bmps are expressed in an overlapping manner at each stage
of nephron development [43,56]: Bmp7 is expressed in
the nephrogenic mesenchyme, and subsequently remains
localized to distal tubules and podocytes. Bmp2 is first
expressed in the renal vesicle, and subsequently becomes
localized to distal tubules, whereas Bmp4 is expressed in
the proximal tubule, and Bmp3 is expressed in Bowman's
capsule. In synthesizing this data, we find no clear corre-
lation between ligand expression and pathway activation
in the nascent nephron. Other components of the path-
way that have been studied provide limited insight into
the pattern of activation. For example, SMAD4 is down
regulated in condensing nephrogenic mesenchyme [59],
providing a possible explanation for the lack of activation
in this compartment. Also, the gene encoding the BMP
antagonist USAG-1 is expressed in the developing distal
tubule, potentially explaining the limited BMP activation
in this segment of the nephron [66]. However, transcripts
for the BMP type 1 and 2 receptors can be found through-
out the developing nephron [67]. Counterintuitively, the
BMP agonist crossveinless 2 is expressed in nephrogenic
mesenchyme and regionally in the comma shaped body
[68]. A caveat to these comparisons is of course that most
expression data is based on transcript analysis, which does
not necessarily correspond with production of active pro-
tein. Therefore, only negative in situ hybridization results
constitute data that can be fruitfully interpreted. An in
vivo reporter is thus an extremely valuable tool in design-
ing further studies of the BMP pathway in nephron mor-
phogenesis based on conditional gene inactivation.
Glomeruli
High power micrographs reveal that signaling is regional-
ized within the glomerulus. Podocytes display little or no
signaling in contrast to cells of Bowman's capsule (Fig.
4T). To locate pathway activation in the core of the devel-
oping glomerulus, we performed X-gal and CD31 staining
on adjacent sections from E17.5 BRE-lacZ kidneys (Fig.
4U, V). Staining for the CD31 endothelial cell marker
overlaps with reporter activation, demonstrating that the
pathway is activated in the glomerular capillary. Interest-
ingly, presumptive mesangial cells display little pathway
activation (Fig. 4U). Our findings correlate with the pat-
tern of nuclear accumulation of pSMAD1/5/8 (Fig. 4L),
and one previous study [69], in which it was furthermore
shown that paracrine BMP signaling from podocytes to
the endothelium significantly affects formation of the
glomerular vasculature. Bmp7 is strongly expressed in the
developing podocyte, but the early onset of aberrant
development precludes detailed analysis of glomerulus
formation in the Bmp7 loss of function mutant.
As a first step toward understanding the molecular basis
for requirement of BMP signaling in the developing kid-
ney at the cellular level, we performed a series of organ
culture experiments in which we treated explanted kid-
neys with recombinant BMPs. Considering the surprising
lack of signaling in the nephrogenic zone, our primary
question was whether this region is refractory to SMAD
dependent BMP signaling, or whether it can be ectopically
activated by growth factor treatment. In serum free culture
conditions, addition of up to 50 ng/ml BMP4 to the cul-
ture medium does not cause reporter activation in theBMC Developmental Biology 2008, 8:86 http://www.biomedcentral.com/1471-213X/8/86
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nephrogenic mesenchyme (Fig 5A–C), indicating that this
cell population is indeed refractory to SMAD-dependent
signaling. To control for the possibility that the reporter
transgene might be transcriptionally silenced specifically
in the nephrogenic mesenchyme, we performed an exper-
iment in which transcription of the transgene was acti-
vated by heat shock to 42° for 2 hours. We find that heat
shock activates transgene transcription in all cells of the
explant, indicating that there is no confounding silencing
of the transgene, and confirming that nephrogenic mesen-
chyme cells indeed are refractory to SMAD dependent
BMP signaling (Fig. 5D, D'). Interestingly, collecting ducts
do respond to increasing doses of BMP treatment by
reporter activation in the tips (Fig. 5A'–C'). Studies have
previously shown that BMP treatment of explanted kid-
neys causes inhibition of collecting duct growth and
branching [65,70]. Cultures of collecting ducts in isola-
tion have demonstrated that this is a direct effect rather
than an effect mediated through the mesenchyme [71].
Our study indicates that high doses of BMP treatment
function to ectopically activate SMAD dependent signal-
ing specifically in the tip of the collecting duct, offering a
possible explanation for the growth inhibitory function of
BMP treatment. In support of this, low doses of BMP7 in
culture have been proposed to stimulate growth and
branching of collecting duct cells through activation of
SMAD independent signaling pathways, whereas high
doses inhibit growth and branching through activation of
SMAD dependent signaling [64,70].
Conclusion
The BRE-lacZ BMP reporter correlates well with immu-
noassays for pathway activation in the peripheral and cen-
tral nervous system, gut, liver, lung, heart, vasculature,
skin, developing bone and kidney, offering advantages in
sensitivity and consistency over immunostaining for
detection of pathway activation. A significant further
advantage is the possibility to use the BRE-lacZ reporter in
organ and primary cell culture experiments to explore
pathway activation in response to experimental manipu-
lation such as growth factor or chemical inhibition treat-
ments. Using the reporter we have for the first time
generated a detailed map of cellular targets of BMP signal-
ing in the developing kidney, making the surprising find-
Specific reporter gene activation is maintained in kidney organ culture supplemented with BMP4 Figure 5
Specific reporter gene activation is maintained in kidney organ culture supplemented with BMP4. A – C. Strong 
reporter gene activation can be seen in collecting ducts of kidneys cultured for 48 hours in serum free medium with or without 
addition of BMP4, whereas the nephrogenic mesenchyme is devoid of reporter activation. A', B'. In untreated cultures, or cul-
tures treated with a low dose of BMP4, reporter gene activation is limited to the collecting duct trunk. C'. At high dose of 
BMP4 treatment, the reporter is ectopically activated in collecting ducts tips. D. To control for the possibility that the trans-
gene is inactivate specifically in the nephrogenic mesenchyme, transgene expression was activated by 120 minutes heat shock at 
42°C. Strong expression of the transgene is seen throughout the organ. D'. Heat shocked wild type kidney explant demon-
strating absence of background staining. Abbreviations: CD: collecting duct, NM: nephrogenic mesenchyme, Ti: collecting duct 
tip, Tr: collecting duct trunk.
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ing that the nephrogenic progenitor cell population is
refractory to SMAD dependent BMP signaling, and that
the nascent nephron displays graded pathway activation.
Furthermore, we find that the BMP pathway is not nor-
mally activated in collecting duct tips, but that it can be
ectopically activated by treatment with recombinant
BMPs, offering a possible explanation for the inhibitory
effects of BMP treatment on collecting duct growth and
branching. The molecular differences between nephro-
genic mesenchyme and collecting duct cells, which most
likely underlie their differential responses to BMPs consti-
tute an interesting area for further research.
Methods
Transgenic reporter construct
To generate the BRE-Hspa1a-lacZ transgene, first, a pBS-
BRE plasmid intermediate was created. The ~94 bp (Id1-
BRE)2 enhancer fragment from the (BRE)2-luc plasmid
[15] (kindly provided by Dr. Peter ten Dijke) was excised
by NheI digestion and subcloned into SpeI linearized,
dephosphorylated (Antarctic Phosphatase, New England
Biolabs) pBS-KSII (Stratagene). Resultant clones were
screened for insert by BssHII digestion. The
pBShsp68lacZpA plasmid [28] (kindly provided by Dr.
Brigid Hogan), was digested with SalI-XmnI and the 4.3
kb Hspa1alacZpA promoter β-galactosidase-polyA fusion
was subcloned (1:1 insert:vector ligation) into SalI linear-
ized and dephosphorylated pBS-BRE. A LacZ primer (5'-
CCTGGAGCCCGTCAGTATCG-3') was paired with Strata-
gene T3 primer (5'-AATTAACCCTCACTAAAGGG-3') to
screen resultant clones for orientation by whole cell lysate
PCR. Clones with the BRE in the same orientation relative
to the promoter as the original (BRE)2-luc were selected.
For BRE-Hspa1a-lacZ, NotI – XmnI digestion was used to
separate the 4.5 kb transgene from the vector backbone.
To generate a neomycin resistance transgene, the 1.9 kb
loxP-flanked pgk-neor gene was separated from vector
backbone of the PL452 construct [72] (kindly provided by
Dr. Neal Copeland) by EcoRI – BamHI digestion. Trans-
genes were gel purified, ethanol precipitated and resus-
pended in endotoxin free TE to 1 mg/ml for BRE-Hspa1a-
LacZ and 0.5 mg/ml for pgk-neor. Genotyping primers
were designed to span the Hspa1a-LacZ junction:
AC087117-F1 5'- TCTTGTCCATTCCACACAGG-3' and
LacZ_1371R_J01636-1 5'- CTGCAAGGCGATTAAGTTGG-
3', with an expected 622 bp product.
Generation of transgenic mice
Animal care in accordance with the National Research
Council Guide for the Care and Use of Laboratory Ani-
mals was approved by the Institutional Animal Care and
Use Committee of Maine Medical Center. 20 μg of
Hspa1a-lacZ or BRE-Hspa1a-LacZ and 5 μg of pgk-neor
transgene were coelectroporated (500 μF, 0.24 kV, 9 msec
pulse) into 8.24 × 106 TC1 ES cells (passage 11) in 0.5 ml
PBS in a Bio-Rad GenePulser 0.4 cm cuvette. After a 5
minute incubation at room temperature, 1 ml of 37°C ES
growth medium was added to each cuvette. ES growth
medium consisted of HyQ DMEM/High Glucose
(HyClone), 15% Embryomax ES cell fetal bovine serum
(Millipore), 50 μg/ml gentamycin sulfate (Invitrogen),
0.1 mM beta-mercaptoethanol (Sigma) and 500 u/ml
ESGRO (Chemicon). The resultant volume was divided
into four 10 cm dishes of irradiated G418 resistant MEF
feeder cells (passage 4) containing fresh 37°C ES growth
medium. Twenty four hours later, medium was changed
to G418 selective medium (300 μg/ml active concentra-
tion) in 3 plates, while 1 plate was changed to non-selec-
tive ES growth medium. Selective medium was changed
every 1–2 days. After 10 days of G418 selection, 96 ES col-
onies with good morphology were picked from 2 selec-
tion plates for Hspa1a-LacZ, and 192 ES colonies were
picked from three BRE-Hspa1a-LacZ selection plates. Col-
onies were picked in PBS containing calcium and magne-
sium, inoculated into plates containing 25 μl trypsin
(Mediatech), incubated for 10 min at 37°C in a humidi-
fied CO2 incubator, interrupted by addition of 50 μl selec-
tive growth medium, triturated and replica plated in
triplicate onto feeder cells (20 μl cells added to 175 μl
selective growth media). After three days of growth, two of
three replica plates were assayed for BMP responsiveness
as follows. ES cells were serum starved for 2 hours, fol-
lowed by BMP4 treatment (R&D systems, 0 or 20 ng/ml)
in serum free medium for 16 hours. Plates were stained
with X-gal according to routine procedures (0.5 mg/ml X-
gal) and 24 clones from two 96-well BRE-Hspa1a-LacZ
plates were selected based on positive staining for repeat
analysis (0 or 50 ng/ml BMP4) with 16 hours of noggin
pretreatment (100 ng/ml, R&D Systems). Three BRE-
Hspa1a-LacZ lines were selected for robust response to
BMP, expanded and used for C57BL/6J blastocyst injec-
tions. Chimeric founders were mated to ICR females and
the F2 (ICRx129S6) progeny were used in this study.
X-gal staining
E10.5 whole mount embryos and E12.5 vibratome sec-
tions were prepared and stained as described in [29]. For
E17.5 and adult, individual tissues were cryosectioned
and stained. Briefly, tissues were dissected and fixed in 1%
formaldehyde, 0.2% glutaraldehyde for 30 minutes, then
equilibrated in 30% sucrose overnight, embedded in OCT
and sectioned at 5 microns. Sections were stained in 0.5
mg/mL X-gal overnight at 37°C.
Immunohistochemistry
Immunohistochemical analysis was performed on 4%
paraformaldehyde fixed paraffin-embedded tissue sec-
tions using antiserum specific for phosphorylated Smad1/
5/8 (Cell Signaling Technology, 1:50 dilution). Following
de-paraffination and hydration, sections were subjectedBMC Developmental Biology 2008, 8:86 http://www.biomedcentral.com/1471-213X/8/86
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to antigen unmasking by microwave heating for two
cycles of 4 and 6 minutes in antigen retrieval solution
(Dako Cytomation, 1:10 dilution). Sections were incu-
bated at room temperature for 2 hours in the presence of
primary antibody. Anti-rabbit HRP-conjugated secondary
antibody (Amersham Biosciences, 1:500 dilution) was
subsequently applied for 45 minutes at room tempera-
ture. Next, sections were incubated for 3 minutes with
Biotinyl Tyramide Reagent according to manufacturer's
protocol (Perkin Elmer). Vectastain (Vector Laboratories)
was subsequently applied to sections for 30 minutes at
room temperature. Stained cells were visualized using
Sigma Fast 3,3'-diaminobenzidine (Sigma-Aldrich)
according to manufacturer's instructions. Sections were
counter-stained in Mayers Hematoxylin, and mounted
(Cytoseal 60, Richard-Allan Scientific). CD31 staining
was performed as previously described [59].
Lectin staining
Frozen E17.5 kidney sections were X-gal stained as above
for 30 minutes to 1 hour. Subsequently, sections were
incubated at room temperature for 1 hour with either
biotinylated lotus lectin (Vector Laboratories, Burlin-
game, CA, 1:200 dilution) or biotinylated dolichos
biflorus agglutinin (Vector Laboratories, Burlingame, CA,
1:200 dilution). Following washing in PBS, sections were
incubated with Streptavidin Alexa Fluor 488 conjugate
(Molecular Probes, 1:600 dilution). Sections were
mounted using Vectashield as above.
Isolation and culture of murine embryonic fibroblasts
One litter of BRE-lacZ × ICR was harvested at E12.5. Fol-
lowing genotyping by X-gal staining of tails, 4 embryos of
each wt and BRE-lacZ were dissected, removing internal
organs and limbs. Fibroblasts were isolated by incubating
minced embryos at 37°C for 10 minutes in 2 ml Trypsin-
Versene solution (Cambrex Bioscience). Cells were
brought into single cell suspension by trituration. Cells
were plated and maintained in DMEM (Hyclone) supple-
mented with 10% bovine growth serum (Hyclone), 2 mM
L-Glutamine (Invitrogen), 100 u/ml Penicillin (Sigma),
100 μg/ml Streptomycin (Sigma), and 2.5 μg/ml Ampho-
tericin B (Sigma).
BMP4 stimulation and quantification of β-galactosidase
Murine embryonic fibroblasts (MEFs) were seeded in 12-
well plates at a density of 5 × 104 per well. 12 h post plat-
ing media was changed to DMEM supplemented with
10% serum replacement (Invitrogen), L-Glutamine, Peni-
cillin, Streptomycin, and Amphotericin B. Following
serum starvation for 36 hours, cells were stimulated for 16
h with 5, 25, or 50 ng/ml recombinant human BMP4
(R&D Systems). For analysis, cells were lysed using
Reporter Lysis Buffer (Promega). Quantification of β-
galactosidase in cell extracts was performed in 96-well for-
mat according to standard procedures [73] using 2-Nitro-
phenyl-β-D-galactopyranoside substrate (ONPG)
(Sigma). Spectrophotometric readings were normalized
for protein content of samples to control for differences in
cell number between samples.
Immunoblot
Total cellular proteins from MEFs, cultured under serum-
free conditions as above with or without 200 ng/ml nog-
gin (R&D Systems) for 48 hours, was extracted by boiling
in sample buffer containing 4% sodium dodecyl sulfate
(SDS), 120 mM Tris HCl pH 6.8, 180 mM dithiothreitol,
8.7% glycerol, and protease inhibitor according to the
manufacturers' protocol (Roche). Proteins were separated
by 8% SDS-polyacrylamide gel electrophoresis and trans-
ferred to a nitrocellulose membrane (Amersham Bio-
sciences). Antibody specific for phosphorylated SMAD1/
5/8 (Cell Signaling Technology) was used at 1/1000 dilu-
tion and anti-β-tubulin (Santa Cruz Biotechnology) was
used at 1/3000 dilution.
Organ culture
Kidney explants were cultured in serum free conditions as
described in [74]. Following 24 hours culture, explants
were treated either with no growth factor, 5 ng/ml, or 50
ng/ml recombinant human BMP4 protein (R&D Sys-
tems), and harvested for X-gal staining after 24 hours of
stimulation. Metatarsals from E17.5 embryos were dis-
sected free from surrounding tissues and cultured on
Nuclepore filters (Millipore) floating on DMEM supple-
mented with Glutamine, Penicillin, Streptomycin, and
Amphotericin B for 24 hours before X-gal staining.
Abbreviations
BMP: bone morphogenetic protein; BRE: BMP responsive
element; DMEM: Dulbecco's modification of Eagle's
medium; ESC: Embryonic stem cell; lacZ: β-galactosidase;
MEF: murine embryonic fibroblast.
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